Brief: Recursion Reports Interim Phase 1 Clinical Data For Rec-617 Monotherapy
09/12/2024 23:09
Dec 10 (Reuters) - Recursion Pharmaceuticals Inc
RXRX.O :
* RECURSION REPORTS INTERIM PHASE 1 CLINICAL DATA FOR
REC-617
MONOTHERAPY, A POTENTIAL BEST-IN-CLASS CDK7 INHIBITOR, WITH
ENCOURAGING PATIENT RESPONSE AND FAVORABLE TOLERABILITY
* RECURSION PHARMACEUTICALS INC: CONFIRMED PARTIAL RESPONSE
IN
PLATINUM-RESISTANT OVARIAN CANCER PATIENT
* RECURSION PHARMACEUTICALS: 4 PATIENTS DEMONSTRATED A BEST
RESPONSE OF STABLE DISEASE FOR UP TO 6 MONTHS OF TREATMENT
* RECURSION PHARMACEUTICALS INC: REC-617 WELL-TOLERATED WITH
NO
DISCONTINUATIONS DUE TO ADVERSE EVENTS
* RECURSION PHARMACEUTICALS INC: PLANS TO CONTINUE
MONOTHERAPY
DOSE ESCALATION AND INITIATE COMBINATION STUDIES IN 1H 2025
Further company coverage: RXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million